Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned an average recommendation of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $51.40.

A number of research firms have recently commented on DYN. Oppenheimer restated an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Chardan Capital restated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday. Guggenheim boosted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Piper Sandler reissued an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley lifted their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th.

Insider Buying and Selling

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at $4,529,594.76. This represents a 6.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John Cox bought 32,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. The trade was a -133.33 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 158,975 shares of company stock valued at $5,693,789 in the last quarter. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of Dyne Therapeutics by 4.3% during the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after acquiring an additional 352 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after buying an additional 709 shares during the last quarter. KBC Group NV boosted its holdings in shares of Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares during the period. Finally, Amalgamated Bank boosted its holdings in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after buying an additional 796 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 11.2 %

Dyne Therapeutics stock opened at $30.31 on Friday. The stock has a fifty day moving average price of $32.58 and a 200 day moving average price of $35.08. Dyne Therapeutics has a 52 week low of $9.76 and a 52 week high of $47.45. The firm has a market capitalization of $3.04 billion, a P/E ratio of -8.51 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts predict that Dyne Therapeutics will post -2.99 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.